Osimertinib(Tagrix) 40MG & 80MG -(Osimertinib)
Product Name : Osimertinib(Tagrix)
Generic Name : Osimertinib
Formulation : Tablet
Available Pack Size : 30’s
Available Strengths : 40mg & 80mg
Registrations : 01/01/2021
Product Information
Osimertinib (Tagrix) 40mg and 80mg is a third-generation EGFR Tyrosine Kinase Inhibitor (TKI) used to treat EGFR mutation-positive Non-Small Cell Lung Cancer (NSCLC), including patients with the T790M resistance mutation. It works by irreversibly binding to mutated EGFR proteins including T790M, L858R, and exon 19 deletion mutations, blocking the abnormal growth signals that drive lung cancer cell proliferation. Manufactured by Beacon Pharmaceuticals Ltd., Bangladesh and globally supplied by Mediaid Pharmacy with worldwide shipping.
Basic Product Information of Osimertinib (Tagrix) 40mg and 80mg
| Brand Name | Tagrix (Osimertinib) |
| Generic Name | Osimertinib (as Osimertinib Mesylate INN) |
| Drug Class | Third-Generation EGFR Tyrosine Kinase Inhibitor (TKI) and Antineoplastic Agent |
| Available Strengths | 40mg and 80mg |
| Formulation | Film-Coated Tablet |
| Pack Size | 30 Tablets in Alu-Alu Blister Pack |
| Primary Indication | EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) |
| USFDA Approved | Yes. First and only USFDA-approved drug of its kind for EGFR T790M mutation-positive NSCLC. |
| Manufacturer | Beacon Pharmaceuticals Ltd., Mymensingh, Bangladesh |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Registration Date | 01/01/2021 |
| Storage Conditions | Store at room temperature between 20 degrees Celsius and 25 degrees Celsius. Keep in a cool and dry place away from light. Keep out of the reach of children. |
How Osimertinib (Tagrix) Works
Tagrix contains Osimertinib, a highly selective and irreversible EGFR kinase inhibitor. It works by binding irreversibly to specific mutant forms of the epidermal growth factor receptor (EGFR), including the T790M resistance mutation, L858R, and exon 19 deletions, at approximately 9-fold lower concentrations than wild-type EGFR. This selective binding prevents cancer cells from receiving the growth signals they need to divide and spread.
Unlike earlier generation EGFR inhibitors, Tagrix is specifically engineered to spare wild-type EGFR during therapy, reducing non-specific binding and significantly limiting toxicity to healthy cells. Two pharmacologically active metabolites, AZ7550 and AZ5104, contribute to its sustained anti-tumour activity in the plasma. Tagrix has also demonstrated the ability to cross the blood-brain barrier, making it effective against central nervous system (CNS) metastases, which is a critical advantage in advanced NSCLC patients.
In clinical studies, Tagrix significantly extended progression-free survival compared to chemotherapy and earlier-generation EGFR TKIs in EGFR mutation-positive patients, with a median overall survival of 38.6 months.
Indications for Osimertinib (Tagrix)
Tagrix (Osimertinib) is indicated for the following conditions:
|
EGFR T790M Mutation-Positive NSCLC For adult patients with locally advanced or metastatic NSCLC whose disease has progressed following EGFR TKI therapy and who carry the T790M resistance mutation, as detected by an FDA-approved test. |
First-Line EGFR-Mutated NSCLC First-line treatment for patients with metastatic NSCLC harbouring EGFR exon 19 deletions or exon 21 (L858R) mutations. Tagrix is now a recognised first-line standard of care in eligible patients. |
|
Resistance to Prior EGFR TKIs For patients who have developed resistance to first- or second-generation EGFR TKIs such as Gefitinib, Erlotinib, or Afatinib, particularly those who have acquired the T790M gatekeeper mutation. |
CNS Metastases in NSCLC Tagrix demonstrates CNS penetration, making it effective in patients with brain metastases associated with EGFR-mutated NSCLC, an area where earlier generation TKIs had limited efficacy. |
Benefits of Osimertinib (Tagrix) 40mg and 80mg
|
USFDA-Approved Targeted Therapy Tagrix is the first and only USFDA-approved drug specifically indicated for EGFR T790M mutation-positive NSCLC, backed by robust clinical trial evidence. |
Selective EGFR Mutation Targeting Irreversibly inhibits T790M, L858R, and exon 19 deletion EGFR mutations while sparing wild-type EGFR, which minimises toxicity to healthy cells throughout the body. |
CNS Penetration Proven ability to cross the blood-brain barrier, providing therapeutic benefit for patients with CNS metastases. This is a major clinical advantage over earlier EGFR TKIs. |
|
Improved Survival Outcomes Clinical studies show a median overall survival of 38.6 months in Tagrix-treated patients compared to 31.8 months with erlotinib or gefitinib, representing a meaningful improvement in outcomes. |
Affordable Alternative to Tagrisso Tagrix delivers the same active ingredient (Osimertinib) and clinical efficacy as AstraZeneca’s Tagrisso at a fraction of the cost, dramatically improving global patient access to life-saving therapy. |
WHO-GMP Certified Manufacturer Produced by Beacon Pharmaceuticals Ltd. under strict international GMP standards. Beacon is a trusted and quality-verified pharmaceutical manufacturer based in Bangladesh. |
How to Take Osimertinib (Tagrix)
Route: Oral, taken by mouth
Standard dose: 80mg once daily until disease progression or unacceptable toxicity
With food: Can be taken with or without food, at the same time each day
Missed dose: Take the missed dose unless the next scheduled dose is within 12 hours. Do not take a double dose to make up for a missed one.
Difficulty swallowing: Disperse the tablet in 60ml of non-carbonated water only. Stir until dispersed into small pieces and swallow immediately. Do not use carbonated water.
Nasogastric tube administration: Disperse the tablet in 15ml of non-carbonated water, then use an additional 15ml of water to transfer any residues to the syringe. Administer the resulting 30ml liquid as per nasogastric tube instructions with appropriate water flushes of approximately 30ml.
Drug interaction dose adjustment: If co-administration with a strong CYP3A4 inducer is unavoidable, increase the dose to 160mg daily. Resume 80mg three weeks after the inducer is discontinued.
Renal or hepatic impairment: Dose adjustment may be required. Consult your oncologist before starting treatment.
Monitoring and Dosage Adjustments
Regular monitoring is essential during Tagrix treatment. Your healthcare provider will monitor for pulmonary symptoms such as new or worsening cough or shortness of breath, which may indicate interstitial lung disease. Monitoring also includes cardiac function for QTc interval prolongation and cardiomyopathy risk, liver function tests, and blood counts including lymphopenia, thrombocytopenia, anaemia, and neutropenia. Report any new respiratory symptoms, skin reactions, or vision changes to your doctor immediately.
Drug Interactions and Important Information
Avoid concomitant use of Tagrix with strong CYP3A4 inducers such as Rifampicin, Phenytoin, Carbamazepine, and St John’s Wort where possible, as these reduce Osimertinib plasma levels significantly. If unavoidable, increase the dose to 160mg and resume 80mg three weeks after stopping the inducer.
Exercise caution when co-administering with sensitive substrates of CYP3A, BCRP, or CYP1A2 with narrow therapeutic indices, including Fentanyl, Cyclosporine, Quinidine, and Ergot Alkaloids, as Tagrix may alter their plasma concentrations. Always inform your oncologist of all medications you are currently taking.
Side Effects and Precautions
|
Common Side Effects Diarrhoea Rash and dry skin including eczema Nail toxicity including nail and nail bed disorders Nausea and decreased appetite Constipation and stomatitis Lymphopenia, thrombocytopenia and anaemia Dry eye, blurred vision and keratitis Hyponatremia and hypermagnesemia |
Serious Warnings and Precautions Interstitial Lung Disease (ILD) or Pneumonitis. Report any new cough or breathlessness immediately. QTc interval prolongation. Monitor heart rhythm, especially with other QT-prolonging drugs. Cardiomyopathy. Monitor cardiac function regularly during treatment. Keratitis. Report eye pain, light sensitivity or vision changes promptly. Not recommended during pregnancy as it may cause foetal harm. Discontinue breastfeeding during treatment. Avoid live vaccines during treatment. Avoid strong CYP3A4 inducers where possible. |
Who Should Use Osimertinib (Tagrix)?
Tagrix is suitable for adult patients diagnosed with locally advanced or metastatic EGFR mutation-positive Non-Small Cell Lung Cancer (NSCLC), particularly those who have developed the T790M resistance mutation after treatment with first- or second-generation EGFR TKIs, as well as patients requiring first-line treatment for EGFR exon 19 deletion or exon 21 (L858R) mutation-positive NSCLC. It is prescribed by oncologists or specialists experienced in anticancer therapies and requires confirmed EGFR mutation status via an approved diagnostic test before initiation.
Manufacturer: Beacon Pharmaceuticals Ltd.
Beacon Pharmaceuticals Ltd. is a leading pharmaceutical manufacturer based in Mymensingh, Bangladesh, specialising in oncology and specialty medications. Beacon is recognised internationally for its commitment to producing high-quality and affordable medicines under strict WHO-GMP standards. Tagrix, their flagship oncology product, has been tested and used in numerous countries including Vietnam, the Middle East, and across Asia, offering a clinically equivalent and cost-effective alternative to AstraZeneca’s Tagrisso at a significantly lower price.
Global Supplier: Mediaid Pharmacy with Worldwide Shipping
Mediaid Pharmacy is a trusted global supplier of oncology and specialty medications. We ensure Osimertinib (Tagrix) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.
Why Choose Osimertinib (Tagrix) from Mediaid Pharmacy?
Tagrix represents one of the most significant breakthroughs in lung cancer treatment of the past decade. As the generic equivalent of Tagrisso by AstraZeneca, it delivers the same active ingredient, Osimertinib, with the same proven mechanism of action at a dramatically lower cost. Manufactured by the trusted Beacon Pharmaceuticals Ltd. under WHO-GMP standards and distributed globally by Mediaid Pharmacy, Tagrix gives patients worldwide access to precision NSCLC therapy without the financial burden associated with brand-name alternatives. For patients and oncologists seeking a proven, affordable, and accessible Osimertinib option with worldwide delivery, Tagrix from Mediaid Pharmacy is the trusted choice.
Frequently Asked Questions About Osimertinib (Tagrix)
What is Tagrix (Osimertinib) used for?
Tagrix (Osimertinib) is a third-generation EGFR tyrosine kinase inhibitor (TKI) used to treat EGFR mutation-positive Non-Small Cell Lung Cancer (NSCLC). It is specifically indicated for patients with the T790M resistance mutation and as a first-line treatment for EGFR exon 19 deletion or exon 21 (L858R) mutation-positive NSCLC. It is the first and only USFDA-approved drug of its kind for T790M mutation-positive NSCLC.
How should I take Osimertinib (Tagrix)?
The recommended dose is 80mg once daily, taken orally with or without food, at the same time each day. Treatment continues until disease progression or unacceptable toxicity occurs. If a dose is missed, take it unless the next dose is due within 12 hours. Always follow your oncologist’s exact instructions.
What strengths is Tagrix (Osimertinib) available in?
Tagrix is available in 40mg and 80mg film-coated tablets, each supplied in a pack of 30 tablets in Alu-Alu blister packs. The 80mg dose is the standard recommended daily dose. The 40mg strength is used when dose reduction is clinically required by your physician.
Is Tagrix the same as Tagrisso (Osimertinib by AstraZeneca)?
Yes. Tagrix is the generic equivalent of Tagrisso. Both contain the same active ingredient, Osimertinib, in the same dosage form and strength. Tagrix is manufactured by Beacon Pharmaceuticals Ltd. in Bangladesh and is bioequivalent to Tagrisso, delivering the same clinical results at a significantly lower cost.
What are the side effects of Osimertinib (Tagrix)?
Common side effects include diarrhoea, rash, dry skin, nail toxicity, nausea, and decreased appetite. Serious but less common risks include Interstitial Lung Disease (ILD), QTc interval prolongation, cardiomyopathy, and keratitis. Always consult your oncologist for a complete side effect profile and drug interaction assessment before starting treatment.
Can Tagrix (Osimertinib) be taken with other medications?
Strong CYP3A4 inducers such as Rifampicin, Phenytoin, and Carbamazepine should be avoided where possible as they reduce the effectiveness of Osimertinib. If co-administration is unavoidable, your doctor may increase the dose to 160mg. Tagrix may also affect the plasma levels of drugs metabolised by CYP3A, BCRP, or CYP1A2. Always inform your oncologist of all medications you are currently taking.
Is Osimertinib (Tagrix) safe during pregnancy or breastfeeding?
No. Tagrix is not recommended during pregnancy as it may cause foetal harm, including embryolethality and reduced foetal growth based on animal studies. Breastfeeding should be discontinued during treatment. Women of childbearing potential must use effective contraception during therapy. Please consult your physician for complete reproductive safety guidance.
Can I order Osimertinib (Tagrix) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Tagrix (Osimertinib) 40mg and 80mg globally with worldwide shipping. Contact us via WhatsApp, phone, or WeChat at +8801773428128 or email us at info@mediaidpharmacy.com to enquire about pricing, availability, and delivery to your country.
Order Osimertinib (Tagrix) 40mg and 80mg with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
